Rigin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Rigin is the “anti-inflammaging” peptide in the matrikine family, and a key ingredient in Matrixyl 3000 alongside Pal-GHK.
What does it do in my body?
Rigin suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing the chronic low-grade inflammation (“inflammaging”) that accelerates skin aging.
How can it help me?
- Where the science stands: Emerging: 14 studies listed but 0 on-target human trials — most of the 14 are off-target database matches, not skin studies
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Rigin was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Topical-only. Commonly formulated alongside Pal-GHK in commercial blends (Matrixyl 3000). No standalone concentration figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
Rigin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Rigin yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
The “anti-inflammaging” peptide and a key ingredient in Matrixyl 3000 — plausible mechanism, real role in a marketed blend, but the public study list for this exact peptide is sparse and mostly off-target database noise.
| Class | Matrikine / anti-inflammaging peptide — topical cosmetic peptide |
| Mechanism (one line) | Suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells → reduces “inflammaging” |
| Evidence base | Emerging: 14 studies listed but 0 on-target human trials — most of the 14 are off-target database matches, not skin studies |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Rigin is the “anti-inflammaging” peptide in the matrikine family, and a key ingredient in Matrixyl 3000 alongside Pal-GHK.
How it works
Rigin suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing the chronic low-grade inflammation (“inflammaging”) that accelerates skin aging.
What the research shows
The public profile lists 14 studies but 0 on-target human trials, graded Emerging — but most of those 14 are clearly off-target database matches (virology/MAVS-signaling papers, an antifungal-analog study), not skin studies; treat the count as profile noise rather than genuine evidence depth.
OHM’s internal 0035 categorization pass grades Rigin Tier C / green / recommend-eligible, as “Palmitoyl Tetrapeptide-7 (Sederma), small topical anti-inflammation skin trials”.
Honest status: real role in marketed blends (Matrixyl 3000), plausible anti-inflammatory mechanism, but the public study list for this exact peptide is sparse and contaminated by mismatches.
Real-world protocol
Topical-only. Commonly formulated alongside Pal-GHK in commercial blends (Matrixyl 3000). No standalone concentration figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to Rigin was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 14 studies (mostly off-target database matches), 0 on-target human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Sederma topical anti-inflammation trials.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Matrixyl · Syn-Coll · Tripeptide-29 · Palmitoyl Dipeptide-6 · Pal-GHK
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 14 studies (mostly off-target database matches), 0 on-target human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Sederma topical anti-inflammation trials.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Matrixyl · Syn-Coll · Tripeptide-29 · Palmitoyl Dipeptide-6 · Pal-GHK